Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, presented highlights of Phase 1 clinical data for RN0361, a long-acting Apolipoprotein C3 (ApoC3) siRNA. RN0361 ...
It’s not every day you see a horse on the beach. But throughout the week, hundreds of them dipped their hooves in the ocean ...
Regular coffee actually seemed to help people with atrial fibrillation, in one of many studies at the AHA meetings.
A novel once-daily oral PCSK9 inhibitor lowered LDL by up to 60% at 24 weeks in patients with heart disease or at high risk ...
In the United States, 1 in every 250 people has inherited a genetic variant that leads to dangerously high cholesterol levels ...
The noninferiority trial of patients at risk for both bleeding and stroke, in a surprise turn, found standard care to be ...
A study found adults using melatonin for over a year had higher risks of heart failure and hospitalization, though some ...
A conservative transfusion approach after general and vascular surgery was shown to be safe vs. earlier, less restrictive ...
"In general, health care was designed by men for men," says Stacey Rosen, president of the American Heart Association. She ...
Current guidelines for the U.S. and Europe have a recommendation of class 2b, level of evidence B or C for LAAO in patients ...
NEW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac ...
A growing body of evidence shows that pediatric cardiology remains stuck in the first 2 generations of health equity research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback